Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 19/20 | 1.00 |
| ▸ | PDE4C | Q08493 | 18/20 | 1.00 |
| ▸ | PDE4A | P27815 | 12/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 12/20 | 1.00 |
| ▸ | HTR2B | P41595 | 1/20 | 0.75 |
| ▸ | TNF | P01375 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29372989 | 1.00 | PDE4B (1.00) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL537805 | 1.00 | PDE4B (1.00) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| Hydrochloric Acid SCHEMBL3355989 | 0.99 | PDE4B (0.98) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL9977585 | 0.93 | PDE4B (1.00) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL3358462 | 0.93 | PDE4B (1.00) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL1194004 | 0.93 | PDE4B (1.00) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL9977589 | 0.93 | PDE4B (1.00) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL537162 | 0.93 | PDE4B (0.86) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL537193 | 0.91 | PDE4B (0.83) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL7109678 | 0.90 | PDE4B (0.84) | PDE4BPDE4CPDE4APDE4DHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 139 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115073354-A | Preparation method of apremilast intermediate | 江苏润安制药有限公司 | 2022-09-20 | — | — | CN | claimed |
| US-10287248-B2 | Process for the preparation of apremilast | CIPLA LIMITED (IN) | 2019-05-14 | — | — | US | claimed |
| US-20180237390-A1 | IMPROVED PROCESS FOR THE PREPARATION OF APREMILAST | CIPLA LIMITED (IN) | 2018-08-23 | — | — | US | claimed |
| EP-3271330-A1 | IMPROVED PROCESS FOR THE PREPARATION OF APREMILAST | Cipla Limited (IN) | 2018-01-24 | — | — | EP | claimed |
| WO-2016146990-A1 | IMPROVED PROCESS FOR THE PREPARATION OF APREMILAST | CIPLA LIMITED (IN) | 2016-09-22 | — | — | WO | claimed |
| EP-2305248-B1 | Substituted phenethylsulfones and method of reducing tnf-alpha levels | CELGENE CORP (US) | 2013-05-08 | — | — | EP | claimed |
| EP-2305248-A1 | Substituted phenethylsulfones and method of reducing tnf-alpha levels | CELGENE CORPORATION (US) | 2011-04-06 | — | — | EP | claimed |
| EP-1752148-A2 | Substituted phenethylsulfones for the treatment of inflammatory, infectious, immunological or malignant disease | CELGENE CORPORATION (US) | 2007-02-14 | — | — | EP | claimed |
| EP-1126839-B1 | SUBSTITUTED PHENETHYLSULFONES AND METHOD OF REDUCING TNF-ALPHA AND PDE-IV LEVELS | CELGENE CORP (US) | 2007-01-03 | — | — | EP | claimed |
| EP-1126839-A4 | SUBSTITUTED PHENETHYLSULFONES AND METHOD OF REDUCING TNF ALPHA LEVELS | CELGENE CORP (US) | 2004-10-27 | — | — | EP | claimed |
| EP-1126839-A1 | SUBSTITUTED PHENETHYLSULFONES AND METHOD OF REDUCING TNF ALPHA LEVELS | CELGENE CORPORATION (US) | 2001-08-29 | — | — | EP | claimed |
| WO-2000025777-A1 | SUBSTITUTED PHENETHYLSULFONES AND METHOD OF REDUCING TNFαLEVELS | CELGENE CORPORATION (US) | 2000-05-11 | — | — | WO | claimed |
| US-6020358-A | REDUCING TUMOR NECROSIS FACTOR CONCENTRATION | CELGENE CORPORATION (US) | 2000-02-01 | — | — | US | claimed |
| EP-4175943-B1 | DUAL-FUNCTIONAL COMPOUNDS AND METHODS OF USE | BIOFRONT THERAPEUTICS BEIJING CO LTD (CN) | 2026-02-11 | — | — | EP | disclosed |
| US-12522612-B2 | PDE4 inhibitors, pharmaceutical compositions, and therapeutic applications | BIOTHERYX INC. (US) | 2026-01-13 | — | — | US | disclosed |
| US-11987556-B2 | Dual-functional compounds and methods of use | BIOFRONT THERAPEUTICS (BEIJING) CO., LTD. (CN) | 2024-05-21 | — | — | US | disclosed |
| US-6020358-A | REDUCING TUMOR NECROSIS FACTOR CONCENTRATION | CELGENE CORPORATION (US) | 2000-02-01 | — | — | US | disclosed |
| US-6020358-A | REDUCING TUMOR NECROSIS FACTOR CONCENTRATION | CELGENE CORPORATION (US) | 2000-02-01 | — | — | US | disclosed |
| US-6011050-A | Substituted phenethylsulfones and method of reducing TNFα levels | CELGENE CORPORATION (US) | 2000-01-04 | — | — | US | disclosed |
| US-6011050-A | Substituted phenethylsulfones and method of reducing TNFα levels | CELGENE CORPORATION (US) | 2000-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180237390-A1 | IMPROVED PROCESS FOR THE PREPARATION OF APREMILAST | ACE, CMA1, APRT | PDE4B 174/4885PDE4C 556/4885PDE4A 127/4885 |
| US-11987556-B2 | Dual-functional compounds and methods of use | PDE1A, PDE3B, PDE1B | PDE4B 19/4885PDE4C 15/4885PDE4A 16/4885 |
| US-10287248-B2 | Process for the preparation of apremilast | ACE, CMA1, AGTR1 | PDE4B 149/4885PDE4C 494/4885PDE4A 124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.